ReviewCardiovascular drugs and therapy1995
Muscarinic receptors and drugs in cardiovascular medicine.
Review in Cardiovascular drugs and therapy, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- The influence of small fibre muscle mechanoreceptors on the cardiac vagus in humans.The Journal of physiology · 2005Trial
- Ethanolic Extracts of Cupressaceae Species Conifers Provide Rapid Protection against Barium Chloride-Induced Cardiac Arrhythmia.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Synaptic Secretion and Beyond: Targeting Synapse and Neurotransmitters to Treat Neurodegenerative Diseases.Oxidative medicine and cellular longevity · 2022Review
- Autonomic regulation of T-lymphocytes: Implications in cardiovascular disease.Pharmacological research · 2019Review
- Muscarinic Receptor Type-3 in Hypertension and Cholinergic-Adrenergic Crosstalk: Genetic Insights and Potential for New Antihypertensive Targets.The Canadian journal of cardiology · 2019Article
- Peri-arterial Autonomic Innervation of the Human Ear.Scientific reports · 2018Article
- The Newly Synthesized Pyrazole Derivative 5-(1-(3 Fluorophenyl)-1Frontiers in physiology · 2018Article
- Changes of phasic and tonic smooth muscle function of jejunum in type 2 diabetic Goto-Kakizaki rats.World journal of diabetes · 2013Article
- Perivascular innervation: a multiplicity of roles in vasomotor control and myoendothelial signaling.Microcirculation (New York, N.Y. : 1994) · 2013Review
- Cross-pharmacology analysis of G protein-coupled receptors.Current topics in medicinal chemistry · 2011Article
- A novel chemogenomics analysis of G protein-coupled receptors (GPCRs) and their ligands: a potential strategy for receptor de-orphanization.BMC bioinformatics · 2010Article
- Effects of cholinesterase inhibition in supraspinal and spinal neural pathways on the micturition reflex in rats.BJU international · 2009Article
- Segment-dependent expression of muscarinic acetylcholine receptors and G-protein coupling in the equine respiratory tract.Veterinary research communications · 2007Article
- Functional M3 muscarinic acetylcholine receptors in mammalian hearts.British journal of pharmacology · 2004Review
- The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction.American journal of physiology. Regulatory, integrative and comparative physiology · 2004Article
- The cholinomimetic agent bethanechol activates IK(ACh) in feline atrial myocytes.Naunyn-Schmiedeberg's archives of pharmacology · 2003Article
- Pilocarpine modulates the cellular electrical properties of mammalian hearts by activating a cardiac M3 receptor and a K+ current.British journal of pharmacology · 1999Article
- Vascular physiology of a Ca2+ mobilizing second messenger - cyclic ADP-ribose.Journal of cellular and molecular medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The parasympathetic system and its associated muscarinic receptors have been the subject of a renaissance of interest for the following two main reasons: (1) the association of endothelial muscarinic receptors and the nitric oxide (NO) pathway; (2) the discovery of several muscarinic receptor subtypes and drugs interacting with them. In the present survey modern insights into the subdivision of muscarinic receptors have been dealt with as the basis for a description of the muscarinic receptor agonists and antagonists thus far known. There are at least four pharmacologically defined M receptors (M1, M2, M3, M4) in primary tissues, and five muscarinic receptors have been cloned (m1, m2, m3, m4, m5). Selective agonists for M-receptor subtypes hardly exist, and all classical agonists (acetylcholine, carbachol, etc.) are clearly nonselective. A few selective antagonists for M1 (pirenzepine) and M2 receptors (AF-DX 116) have been introduced, although selective M3 receptors are hardly available. Finally, the potential therapeutic use of M-receptor agonists (myocardial ischemia, hypertension) and muscarinic antagonists (certain forms of bradycardia, coronary spasm) has been critically discussed. Although only in a preliminary stage, this development appears to be promising and at least of great fundamental interest.
Indexed as
Identifiers
7786837What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.